Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 24;17(8):e0272648.
doi: 10.1371/journal.pone.0272648. eCollection 2022.

Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada

Affiliations

Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada

Pierre-Philippe Piché-Renaud et al. PLoS One. .

Abstract

Background: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical management and public health interventions. The objective of this study was to describe the clinical manifestations, disease severity, and characteristics associated with hospitalization among infants infected with the initial strains of SARS-CoV-2.

Methods: This is a national, prospective study of infants with SARS-CoV-2 from April 8th 2020 to May 31st 2021 using the infrastructure of the Canadian Paediatric Surveillance Program. Infants <1 year of age with microbiologically confirmed SARS-CoV-2 infection from both inpatients and outpatients seen in clinics and emergency departments were included. Cases were classified as either: 1) Non-hospitalized patient with SARS-CoV-2 infection; 2) COVID-19-related hospitalization; or 3) non-COVID-19-related hospitalization (e.g., incidentally detected SARS-CoV-2). Case severity was defined as asymptomatic, outpatient care, mild (inpatient care), moderate or severe disease. Multivariable logistic regression was performed to identify characteristics associated with hospitalization.

Results: A total of 531 cases were reported, including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19. Amongst all cases with SARS-CoV-2 infection, the most common presenting symptoms included fever (66.5%), coryza (47.1%), cough (37.3%) and decreased oral intake (25.0%). In our main analysis, infants with a comorbid condition had higher odds of hospitalization compared to infants with no comorbid conditions (aOR = 4.53, 2.06-9.97), and infants <1 month had higher odds of hospitalization then infants aged 1-3 months (aOR = 3.78, 1.97-7.26). In total, 20 infants (3.8%) met criteria for severe disease.

Conclusions: We describe one of the largest cohorts of infants with SARS-CoV-2 infection. Overall, severe COVID-19 in this age group was found to be uncommon. Comorbid conditions and younger age were associated with COVID-19-related hospitalization amongst infants.

PubMed Disclaimer

Conflict of interest statement

JP reports grants to his institution from MedImmune, Merck, Sanofi Pasteur and AbbVie, and speaker fees from AbbVie and AstraZeneca, all outside of the submitted work. MS is supported via salary awards from the BC Children’s Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. PPPR has been co-investigator on an investigator-led project funded by Pfizer that is unrelated to this study. RP is a consultant for Verity Pharmaceuticals. SKM is co-principal investigator on an investigator-led grant from Pfizer, has served on an ad-hoc advisory boards for Pfizer and Sanofi Pasteur, and has received speaker fees from GlaxoSmithKline, all unrelated to this study. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Flow chart of cases reported to the CPSP COVID-19 study until May 31, 2021.
Fig 2
Fig 2
a. Cases of SARS-CoV-2 infection among infants reported to the CPSP, by Canadian region*. *Western/Northern Canada includes Alberta, British Columbia, Manitoba, Northwest Territories, Nunavut, Saskatchewan, and Yukon. Atlantic Canada includes Newfoundland & Labrador, New Brunswick, Nova Scotia, and Prince Edward Island. b. Cases of SARS-CoV-2 infection among infants reported to the CPSP, by admission status.

Similar articles

Cited by

References

    1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 7 Apr 2020;323(13):1239–42. doi: 10.1001/jama.2020.2648 - DOI - PubMed
    1. Zhou F, Yu T, Du R, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 28 March 2020;395(10229):1054–62. doi: 10.1016/S0140-6736(20)30566-3 - DOI - PMC - PubMed
    1. Tostmann A, Bradley J, Bousema T, et al.. Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020. Eurosurveillance. 23 avr 2020;25(16):2000508. doi: 10.2807/1560-7917.ES.2020.25.16.2000508 - DOI - PMC - PubMed
    1. Arentz M, Yim E, Klaff L, et al.. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 28 Apr 2020;323(16):1612–4. doi: 10.1001/jama.2020.4326 - DOI - PMC - PubMed
    1. Guan W, Ni Z, Hu Y, et al.. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 30 Apr 2020;382(18):1708–20. doi: 10.1056/NEJMoa2002032 - DOI - PMC - PubMed

Publication types